Karyopharm Therapeutics (NASDAQ:KPTI) Lowered to “Hold” Rating by StockNews.com

StockNews.com cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research report report published on Friday.

A number of other research analysts have also issued reports on KPTI. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Piper Sandler increased their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Up 8.7 %

KPTI opened at $0.85 on Friday. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95. The business’s 50 day moving average is $0.83 and its 200-day moving average is $0.89.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the firm posted ($0.30) earnings per share. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth $494,000. GSA Capital Partners LLP raised its position in Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after buying an additional 792,283 shares during the period. Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $167,000. Finally, Point72 DIFC Ltd purchased a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $31,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).